Money has gushed into the biotech industry over the last couple of years, as the pandemic brought the industry onto center stage. At the same time, tech investors have rushed into the arena.
Who has benefited the most?
STAT analyzed yearly financial records from more than four dozen biotech investment firms that laid out their assets, both in liquid cash and also biotech stock portfolios, to determine which have seen the most growth over time.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect